Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features - An exploratory analysis of placebo-controlled trials

Journal of Bone Oncology

Volumn 2, Issue 2, 2013, Pages 70-76

  Coleman, Robert E ^a   Lipton, Allan ^b   Costa, Luis ^c   Cook, Richard J ^d   Lee, Ker Ai ^d   Saad, Fred ^e   Brown, Janet E ^a,f   Terpos, Evangelos ^g   Major, Pierre P ^h   Kohno, Norio ⁱ   Smith, Matthew ^j   Body, Jean Jacques ^k  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d UNIVERSITY OF WATERLOO   (Canada)

^e NOTRE DAME HOSPITAL   (Canada)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ TOKYO MEDICAL UNIVERSITY   (Japan)

^j MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^k BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

Breast cancer; N telopeptide of type I collagen; Non small cell lung cancer; Prostate cancer; Survival Zoledronic acid

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PLACEBO; TESTOSTERONE; ZOLEDRONIC ACID;

ADVANCED CANCER; ALBUMIN BLOOD LEVEL; ARTICLE; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MULTICENTER STUDY; OSTEOLYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD COMPRESSION; TESTOSTERONE BLOOD LEVEL;

EID: 84882312455     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2013.01.002     Document Type: Article

References (35)

1. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bispho-sphonates in solid tumours: recommendations of an international expert panel. Annals of Oncology 2008;19: 420-32.
2. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Journal of Clinical Oncology 2001;19: 558-67. (Pubitemid 32112871)
3. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. Journal of Clinical Oncology 2005;23: 3314-21.
4. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of National Cancer Institute 2002;94: 1458-68.
5. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Journal of Clinical Oncology 2003;21: 3150-7. (Pubitemid 46606297)
6. Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. British Journal of Cancer 2010;102: 1099-105.
7. Coleman R, de Boer R, Eidtmann H. et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letro-zole (ZO-FAST study): final 60-month results. Annal of Oncology 2012;.Oct 9th, E-pub ahead of print.
8. Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncology 2011;12: 631-41.
9. Guise TA. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treatment Reviews 2008;34(suppl 1): S19-24.
10. Morgan G, Davies F, Gregory W, et al. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood 2012;119(23): 5374-83.
11. Mystakidou K, Katsouda E, Parpa E, et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Medical Oncology 2005;22: 195-201. (Pubitemid 41003454)
12. Zaghloul MS, Boutrus R, El-Hossieny H, et al. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. International Journal of Clinical Oncology 2010;15: 382-9.
13. Zarogoulidis K, Boutsikou E, Zarogoulidis P, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. International Journal of Cancer 2009;125: 1705-9.
14. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine 2011;365: 1396-405.
15. Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110: 1860-7. (Pubitemid 47557312)
16. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. Journal of the National Cancer Institute 2005;97: 59-69.
17. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. Journal of Clinical Oncology 2005;23: 4925-35. (Pubitemid 46223998)
18. Noguchi M, Kikuchi H, Ishibashi M, et al. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. British Journal of Cancer 2003;88: 195-201. (Pubitemid 36255835)
19. Lam PT, Leung MW, Tse CY. Identifying prognostic factors for survival in advanced cancer patients: a prospective study. Hong Kong Medical Journal 2007;13: 453-9. (Pubitemid 351206680)
20. Paralkar VR, Li T, Langer CJ. Population characteristics and prognostic factors in metastatic non-small-cell lung cancer: a Fox Chase Cancer Center retrospective. Clinical Lung Cancer 2008;9: 116-21. (Pubitemid 351631924)
21. Seve P, Ray-Coquard I, Trillet-Lenoir V, et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer 2006;107: 2698-705. (Pubitemid 44845626)
22. Vigano A, Bruera E, Jhangri GS, et al. Clinical survival predictors in patients with advanced cancer. Archives of Internal Medicine (Chicago, IL) 2000;160: 861-8. (Pubitemid 30165248)
23. Barbot AC, Mussault P, Ingrand P, et al. Assessing 2-month clinical prognosis in hospitalized patients with advanced solid tumors. Journal of Clinical Oncology 2008;26: 2538-43.
24. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008;113: 193-201. (Pubitemid 351976401)
25. Lipton A, Cook RJ, Major P, et al. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. The Oncologist 2007;12: 1035-43. (Pubitemid 350007015)
26. Cox DR. Regression models of life tables (with discussion). Journal of the Royal Statistical Society: Series B (Statistical Methodology) 1972;34: 187-220.
27. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. Hoboken, NJ: John Wiley & Sons; 2002 462 p.
28. Lawless JF. Statistical models and methods for lifetime data. Hoboken, NJ: John Wiley & Sons; 2003 630 p.
29. Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. Journal of Thoracic Oncology 2008;3: 228-36. (Pubitemid 351654321)
30. Major PP, Cook RJ, Lipton A, et al. Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer 2009;9: 272.
31. Chua W, Charles KA, Baracos VE, et al. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. British Journal of Cancer 2011;104: 1288-95.
32. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377: 813-22.
33. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of Clinical Oncology 2011;29: 1125-32.
34. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Journal of Clinical Oncology 2010;28: 5132-9.
35. Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clinical Cancer Research 2003;9: 2394-9. (Pubitemid 36842077)